The firm has seen a small handful of false positives for the test in thousands of samples run since the study, but attributed them to biological features.
The company is developing a non-invasive test that analyzes only a small area of the genome to infer overall tumor mutational load to help guide immunotherapy use.
The money will support efforts by the company to develop liquid biopsy methods that can serve patients that its current tissue-based testing does not.
MD Anderson aims to rapidly collect clinical utility data to support decisions by relevant committees to broadly offer the test and to begin persuading payors to reimburse.
The company plans to develop a liquid biopsy assay that can identify patients most likely to benefit from treatment with checkpoint inhibitors.
Guardant will help MD Anderson develop new assays and conduct clinical studies, and physicians will be able to order the company's test through an EMR system.
Milenia will exclusively offer the test to patients through its network of 12 diagnostic centers in Mexico, and will also make future assays available.
The collaborators will explore the use of cell-free DNA for preimplantation genetic testing.
The distributors will promote Trovagene's clinical test services, and will also gain access to the research-use kits the firm is co-developing with Boreal Genomics.
Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.
In Genome Biology this week: comparative genomics study of Aspergillus, genetic variation in indigenous African cattle, and more.
Some people who harbor genetic variants associated with disease show no signs and may give insight into the continuum of symptoms, Spectrum reports.
Some 57 snow monkeys at a Japanese zoo were found to be rhesus macaque hybrids, which are banned in Japan.
British researchers say they've been removed from EU grant applications, according to the Guardian.